FlexGen to Use VC Money to Speed Commercialization of FlexArrayer | GenomeWeb

NEW YORK (GenomeWeb News) – FlexGen today announced that it has closed a round of private equity financing with an undisclosed amount of funding coming from BioGeneration Ventures and Crédit Agricole Private Equity.

The amount of the funding was in the several million euros, according to FlexGen CEO Fred Dom.

The firm, based in Leiden, The Netherlands, intends to use the money to speed up development and global commercialization of its FlexArrayer for producing custom microarrays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.